Last reviewed · How we verify
Bal (DIMERCAPROL)
At a glance
| Generic name | DIMERCAPROL |
|---|---|
| Sponsor | Provepharm Sas |
| Drug class | alpha-Adrenergic Agonist [EPC] |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | FDA-approved |
| First approval | 1946 |
Approved indications
- Accidental poisoning by lead and its compounds and fumes
- Gold Toxicity
- Mercury Toxicity
- Toxic effect of arsenic AND/OR its compounds
Common side effects
- Rise in blood pressure
- Tachycardia
- Nausea
- Vomiting
- Headache
- Burning sensation in lips, mouth and throat
- Feeling of constriction in throat, chest, or hands
- Pain in throat, chest, or hands
- Conjunctivitis
- Lacrimation
- Blepharal spasm
- Rhinorrhea
Serious adverse events
- Painful sterile abscesses
Key clinical trials
- Effects of Bronchial Segmental Endotoxin Instillation in Humans (PHASE2)
- Microbiota and the Lung Cancer (NA)
- Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial (NA)
- Biobank for the Identification of Biomarkers in Lung Cancer (BIRD, Biomarkers in Respiratory Disease)
- Tissue Biopsy and Imaging Studies in HIV-Infected Patients
- Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax
- Effect of tNGS on CAP Patients With Initial Treatment Failure (NA)
- Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |